Herbert Smith Freehills Kramer Advises Underwriters Of Medtide's Hong Kong IPO

Herbert Smith Freehills Kramer is a world-leading global law firm, where our ambition is to help you achieve your goals. Exceptional client service and the pursuit of excellence are at our core. We invest in and care about our client relationships, which is why so many are longstanding. We enjoy breaking new ground, as we have for over 170 years. As a fully integrated transatlantic and transpacific firm, we are where you need us to be. Our footprint is extensive and committed across the world’s largest markets, key financial centres and major growth hubs. At our best tackling complexity and navigating change, we work alongside you on demanding litigation, exacting regulatory work and complex public and private market transactions. We are recognised as leading in these areas. We are immersed in the sectors and challenges that impact you. We are recognised as standing apart in energy, infrastructure and resources. And we’re focused on areas of growth that affect every business across the world.

Explore Firm Details

Leading global law firm Herbert Smith Freehills Kramer has advised Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited as joint sponsors...

Hong Kong

Leading global law firm Herbert Smith Freehills Kramer has advised Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited as joint sponsors and the underwriters of Medtide Inc. (03880.HK)'s H share listing on the Main Board of the Hong Kong Stock Exchange.

"This listing reflects renewed momentum in Hong Kong's healthcare IPO market, with investor appetite returning," said Hong Kong partner Matt Emsley. "As a global capital hub and China's innovation gateway, Hong Kong remains the destination of choice for healthcare companies seeking international exposure."

Medtide is a peptide-focused CRDMO (Contract Research, Development, and Manufacturing Organisation), offering full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. According to Frost & Sullivan, Medtide is the third largest peptide-focused CRDMO worldwide in terms of sales revenue in 2023.

Medtide listed on the Hong Kong Stock Exchange on 30 June 2025. This is the second healthcare IPO on which the firm has advised in a month.

"We congratulate Medtide on its successful listing on the Hong Kong Stock Exchange," said Beijing partner Stanley Xie. "Our track record in healthcare IPOs speaks to the depth of our sector expertise and commitment to clients' success."

Herbert Smith Freehills Kramer is a leading Hong Kong IPO adviser for healthcare companies. In the past five years, the firm has advised on 26 healthcare company listings on the Hong Kong Stock Exchange, including Jiangsu Hengrui Pharmaceuticals (01276.HK), QuantumPharm Inc. (02228.HK), Lepu ScienTech Medical (02291.HK), Biocytogen Pharmaceuticals (02315.HK), CARsgen Therapeutics (02171.HK), Abbisko (02256.HK), Simcere (02096.HK), among others.

Partners Matt Emsley, Stanley Xie and Jin Kong* jointly led a cross-office team advising the underwriters, assisted by Jaime Fong, Sean Ji, Crystal Chan, Reagan Li and Wang Ting. Primrose Ho, Betty Zhou, Susan Zou and Emily Wan also provided assistance.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation's Digital Legal Delivery business to provide high-efficiency solutions for verification and other document-intensive processes during the listing, assisted by legal specialist Jean Zhou, senior legal analyst Chloe Hu and legal analyst Chunqin Li.

*According to regulatory requirements, Jin Kong's official title is Senior Registered Foreign Lawyer in Hong Kong.

Contributor

Explore Firm Details

See More Popular Content From